Manila Times Business
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 5, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facility will be the Company's key DP facility designed to meet the latest and most stringent requirements for international markets, with expected output of approximately 100 million units of pre-filled syri
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
Just now
From Mythical Prophecy to Realism: The Rational Turn of Hu Jiaqi's Doomsday Philosophy
Just now
Energy Awaits When Summer Comes to Play at Galaxy Macau
Just now
Trip.com Kicks Off Winter Travel Season with EOFY Mega Sale and Massive Flight Perks
Just now